{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:26:47Z","timestamp":1793647607238,"version":"4.5.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhepr.2024.101290","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:43:37Z","timestamp":1732931017000},"page":"101290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data"],"prefix":"10.1016","volume":"7","author":[{"given":"Zhihao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-6069","authenticated-orcid":false,"given":"Daniel","family":"Aliseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8692-6757","authenticated-orcid":false,"given":"Owen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2716-7121","authenticated-orcid":false,"given":"Luckshi","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-949X","authenticated-orcid":false,"given":"Christian","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-403X","authenticated-orcid":false,"given":"Grainne M.","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-4276","authenticated-orcid":false,"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Sapisochin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101290_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2024.101290_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2024.101290_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101290_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2024.101290_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401\u2013MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2024.101290_bib6","doi-asserted-by":"crossref","first-page":"LBA490","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2024.101290_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.jhepr.2024.101290_bib10","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib11","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2024.101290_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jhepr.2024.101290_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jhepr.2024.101290_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/0284186X.2012.682628","article-title":"Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma","volume":"51","author":"Kang","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2017.12.028","article-title":"PICCA study: panitumumab in combination with cisplatin\/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer\u2014a randomised biomarker-driven clinical phase II AIO study","volume":"92","author":"Vogel","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2024.101290_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine\u00a0+ cisplatin in unresectable gallbladder cancer:\u00a0results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2024.101290_bib17","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib18","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cancers12071975","article-title":"Treatment of patients with advanced biliary tract cancer with either oxaliplatin, gemcitabine, and capecitabine or cisplatin and gemcitabine\u2014a randomized phase II trial","volume":"12","author":"Markussen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101290_bib19","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","article-title":"Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study","volume":"22","author":"Valle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/s41416-022-01903-6","article-title":"Randomised, phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer","volume":"127","author":"Doherty","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2024.101290_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101290_bib22","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1200\/JCO.23.01566","article-title":"Nanoliposomal irinotecan with fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced cholangiocarcinoma: a phase II study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315)","volume":"42","author":"Ettrich","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate\u00a0and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2024.101290_bib24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101290_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus\u00a0lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib27","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101290_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(18)30383-2","article-title":"Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial","volume":"4","author":"Yoshikawa","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101290_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib31","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/annonc\/mdu232","article-title":"S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)","volume":"25","author":"Yoshida","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus\u00a0gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101290_bib33","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib34","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib35","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhepr.2024.101290_bib36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhepr.2024.101290_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:28:51Z","timestamp":1741652931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2589555924002945"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101290"}}